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Abstract
IntroductionThe aim of this paper is to propose a transparent, alternative approach for network meta-analysis based on a regression model that allows inclu-sion of studies with three or more treatment arms.
MethodologyBased on the contingency tables describing the frequency distribution of the outcome in the different inter-vention arms, a data set is constructed. A logistic regression is used to deter-mine the parameters describing the 
difference in effect between a specific intervention and the reference inter-vention and to check the assumptions needed to model the effect param-eters. The method is demonstrated by re-analysing 24 studies investigating the effect of smoking cessation inter-ventions. The results of the analysis were similar to two other published approaches to network analysis using the same data set. The presence of heterogeneity, including inconsist-ency, was examined.
ConclusionThe proposed method provides an easy and transparent way to  estimate 
treatment effect parameters in meta-analyses involving studies with more than two arms. It has several addi-tional attractive features such as not overweighting small studies as the random effect models do, deal-ing with zero count cells, checking of assumptions about the distribution of model parameters and investiga-tion of heterogeneity across trials and between direct and indirect evidence.
IntroductionIncluding indirect comparisons in meta-analysis can be of value when evidence from head-to-head compar-isons is not or only sparsely available, to increase the precision of any meta-analysis of the direct comparisons 
or to formally rank the benefits of a larger set of different treatments1,2. An even more imperative reason for inclusion of indirect comparisons is that valid data should not be ignored and like all other pertinent evidence should be included in the meta- analysis. As Fisher3 said: ‘All statisti-
cians know that data are falsified if only a selected part is used’.To compare the effects of more than two competing treatments, several methods have been proposed to pool all available evidence in one network analysis. Some methods1,4 cannot be applied when trials with more than two treatment arms are included. A method that solves this problem is the Mixed Treatment Comparisons based on a Bayesian model2. Given the likelihood function based on the data collected in the studies, this method assumes a number of prior distribu-tions which generate the posterior distribution of the effect parameters. We propose an approach based on an ordinary regression model in which all available information is pooled with respect to the difference 
in effect of two or more treatments (i.e. combining all information from direct and indirect comparisons). The outline of this paper is as  follows. First, we describe the method using studies with binary outcomes and demonstrate the method with a data set of 24 studies which investigated the effect of smoking cessation inter-ventions. We compare the results of our analysis with those of two other published approaches to net-work analysis (i.e. Hasselblad, and Lu and Ades (Bayesian hierarchical model))2,5,6 that had previously been applied to the same data set. In the next section we discuss the causes of heterogeneity (i.e. the difference in effect estimates between studies that cannot be explained by chance alone)7. This includes inconsistency of results between direct and indi-rect comparisons for the same treat-ment contrast. Next, we show how heterogeneity can be modelled and its causes investigated. In the last sec-tion we discuss some features of our approach and show how the method can be expanded to trials with inter-val scaled outcomes.
MethodologyThe authors have referenced some of their own studies in this method-ology. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the insti-tution in which they were performed. All human subjects, in these refer-enced studies, gave informed consent to participate in these studies.
Description of the methodFrom the difference in outcomes between treatment A and B and the 
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difference between treatment A and C, the difference between treatment B and C can be deduced. In a network analysis the results of these indirect comparisons as well as the results of studies comparing the outcome of treatments B and C directly are used to generate the overall result.A network analysis using a regres-sion model can be done at three outcome levels. The customary approach8 is to calculate for each study an effect parameter and its variance describing the difference in effect between two treatments. In the second step these effect parame-ters are pooled, and weighted by the inverse of their variances9.A less common approach is to calculate an effect parameter and its variance for each treatment arm separately and use these parameters in a regression model as described by Hasselblad5 and Berlin et al.10. Both the methods are two-step approaches. First an effect parameter per study or study arm is determined and in the second step the results are pooled. The pooling leads to distinguish-ing within-study or study treatment arms variance from between-study or study treatment arms variance.What we propose here is a one-step approach that uses the data at the patient level. With the reported two-by-two contingency table a data 
file can be constructed in which each of the contributing patients is repre-sented by a record with one variable describing the study (Si, i = 1, 2…N), one variable describing the treat-ment (Tk, k = 1, 2…K) and a variable describing the outcome Y (zero or one). In this way the original study population data set is reconstructed. Of course, patient-level information on covariates is not available.In a logistic regression model using dummy variables to code for the stud-ies and treatments, the logarithm of the odds (LnOdds) of the outcome Y for each patient can be written as:
LnOdds Y S Ti k i k( )= | = +1 ∩ α β  (1)
Where αi is the LnOdds of treatment success (or failure) in study Si for the reference treatment (for example a 
placebo) and βk is the difference of the LnOdds between treatment Tk and the reference treatment. In this model we assume that the treat-
ment effect is constant (fixed) over the studies. In section 3, we will relax this assumption. The study-
specific intercept αi adjusts for dif-
ferences in risk profiles between the study populations and other between-study differences in study 
design. These study-specific inter-cepts adjust for differences across studies. Furthermore, in this one-step analysis, no distinction is made between within- and between- 
variances of the parameter βk and both are included in the variance of 
βk. There is no limitation on the num-ber of treatment arms per study. As each patient is included in the analy-sis only once, this method avoids the problem of using the same patients several times in more than two-armed trials as in the approaches proposed by Lumley4 and Bucher et al.1. Considerations of statistical 
sufficiency show that our approach is equivalent to using grouped logis-tic regression on the outcome counts in each treatment arm. We applied our method to data of 24 studies on the effect of four smoking cessation treatments. These studies compared the effect of four  treatments for smoking  cessation: ‘no contact’ (n = 7231 with 605 cases), ‘self-help’ group (n = 1568 with 155 cases), ‘individual counsel-ling’ (n = 7383 with 1209 cases) and 
‘group counselling’ (n = 555 with 103 cases). Two studies compared three different interventions. A short description of these studies can be found in Supplementary informa-tion. These 24 studies were also used by Hasselblad5 estimating the effect parameters for each treatment arm in a random effect model and by Lu and Ades2 in a Bayesian network analysis6.The results of the different approaches, shown in Table 1, are similar except for the results of the Bayesian model with random effects.In our approach the effect param-
eters and confidence intervals of all possible contrasts can be determined by successively choosing another treatment as the reference category.Furthermore, with this model we can calculate an effect parameter based on the results of the subset of indirect comparisons only. For example, to calculate the result of the indirect contrast, ‘no contact’ versus ‘individual counselling’ we use the same model as described in ‘expression 1’ but exclude all studies 
that investigate this specific contrast directly. Similarly, an overall coef-
ficient based on direct contrast can be calculated by including only direct comparisons.In the analysis of heterogeneity the result of separately pooling the indirect comparisons will be pre-sented as the result of a virtual trial just like the results of the direct com-parisons. In this way, we may explore the extent to which adding indirect 
comparisons influence the outcome of the analysis.
Table 1 Regression coefficients (Log Odds ratios) and corresponding standard 
errors of four different models describing the effect of three treatments for 
smoking cessation as compared with ‘no contact’ as reference
 Our  
analysis
Hasselblad5 Lu and Ades2,6 
Fixed effect
Lu and Ades2,6
Random effect
Self-help 0.23 (0.13) 0.26 (0.17) 0.23 (0.13) 0.52 (0.39)
Individual counselling 0.64 (0.06) 0.64 (0.07) 0.77 (0.06) 0.81 (0.23)
Group counselling 0.83 (0.17) 0.83 (0.26) 0.84 (0.18) 1.16 (0.45)
Methodology
Page 3 of 8
Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)
Co
m
pe
ti
ng
 in
te
re
st
s:
 n
on
e 
de
cl
ar
ed
. C
on
fli
ct
 o
f i
nt
er
es
ts
: n
on
e 
de
cl
ar
ed
.
A
ll 
au
th
or
s 
co
nt
ri
bu
te
d 
to
 t
he
 c
on
ce
pti
on
, d
es
ig
n,
 a
nd
 p
re
pa
ra
ti
on
 o
f t
he
 m
an
us
cr
ip
t,
 a
s 
w
el
l a
s 
re
ad
 a
nd
 a
pp
ro
ve
d 
th
e 
fin
al
 m
an
us
cr
ip
t.
A
ll 
au
th
or
s 
ab
id
e 
by
 t
he
 A
ss
oc
ia
ti
on
 fo
r 
M
ed
ic
al
 E
th
ic
s 
(A
M
E)
 e
th
ic
al
 r
ul
es
 o
f d
is
cl
os
ur
e.
For citation purposes: Kessels AGH, ter Riet G, Puhan MA, Kleijnen J, Bachmann LM, Minder ChE. A simple regression model 
for network meta-analysis. OA Epidemiology 2013 Jul 22;1(1):7.
HeterogeneityThe assumption that the effect of a 
treatment is constant or fixed in all studies is not realistic as the treat-
ment effect (i.e. the parameter βk) can vary from study to study. The effect of a treatment as recorded in a study may 
be modified by population characteris-tics like age, sex, stage of disease, dura-tion and severity of complaints and characteristics of the study set-up, such as duration of follow-up, differences in the application of the intervention or the way the outcome is measured. Furthermore, variation could occur 
through design flaws and imperfec-tions in the conduct of the study.  Studies with severe methodological shortcomings should not be included in a meta-analysis. But, for example, the treatment groups in a trial can show some differences with respect to their prognosis and behaviour and some residual confounding may be 
present. Both effect modification and residual bias can be accounted for by including an interaction term.To do so, the formula of LnOdds becomes:
LnOdds Y S Ti k i k i k( = = + +1| ) ,∩ α β δ (2)
Where δi,k denotes the deviation from 
the overall effect of treatment βk by the interaction between treatment k with study i. The interaction term of the ref-erence treatment and study i is included 
in the study-specific intercept αi. In a two-step analysis the varia tion 
in δi,k describes the heterogeneity 
and it is assumed that δi,k is  normally distributed. The random effects approach is based on this assump-tion. If it is assumed that the included studies are a random sample of a population of possible studies, the random effects approach could be 
justified. However, the design and conduct of a study is the product of a cognitive process, and designs and ways of study conduct could be tailored in various ways. This could result in a non-normal distribution 
through outlying values of δi,k or δi,k having a bimodal or skewed distri-bution and this may have a substan-
tial influence on the estimates of the 
coefficients and their variances. If 
the deviation δi,k is small, there are no important interactions apparent, and a model of type ‘expression 1’ 
is adequate. If the values of δi,k are substantial, model of type ‘expres-sion 2’ is adequate. If, in addition, 
the δi,k are normally distributed, a random effects model may be used. 
Then the variation in the δi,k will be included in the variance of the esti-
mated  parameters βk. Therefore, investigating whether the normal-ity assumption holds and which fac-
tors could modify the interaction δi,k 
(effect modification or bias), should be a part of the meta-analysis. This is demonstrated in the next example using the comparison between ‘no contact’ and ‘individual counselling’.
The distribution of the coefficients of the direct comparisons and the 
coefficient of the combined indirect comparisons are described with the help of a Forest plot and a histogram as shown in Figures 1 and 2.To investigate heterogeneity we used the classical I2-statistic11. A part of the heterogeneity could be caused by including indirect compari-sons in the analysis. The Forest plot in Figure 1 and the tests for hetero-geneity, with and without the indirect  comparison, show that there is het-erogeneity within the direct compari-sons which is not increased by adding the result of the indirect comparisons. Figure 2 shows that the 15 coef-
ficients, βk, which describe the differ-ence in effect between ‘no contact’ versus ‘individual counselling’ appear to follow a bimodal  distribution.The implication of this is that assuming a random effect model 
Figure 1: Forest plot of the coefficients and its estimates (ES) with confidence intervals comparing ‘Individual counseling’ with ‘no contact’ including the coef-
ficient of the combined indirect comparisons as pooled from study 2–5 and 
20–24. At the bottom the tests for heterogeneity of the direct comparisons and all comparisons are shown.
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Table 2 The results (Log Odds ratios) of indirect and direct comparisons and 
their differences with standard errors in brackets
 Direct 
comparisons
Indirect
comparisons
Difference P-value of 
difference
Self-help 0.14 (0.14) 0.52 (0.26) −0.38 (0.30) 0.20
Individual counselling 0.64 (0.06) 0.42 (0.30) 0.22 (0.31) 0.40
Group counselling 0.86 (0.43) 1.00 (0.21) −0.14 (0.48) 0.79
Figure 2: Histogram of the coefficients βk describing the difference in effect between the ‘individual counselling’ and the ‘no contact’ groups. The composite 
coefficient based on indirect comparisons is 0.42.might well give erroneous results. Looking more closely at the differ-ences between the characteristics of the 11 utmost-left and four utmost-right studies could give some clue for the causes of the bimodality. Stratify-ing the analysis in this way resulted 
in two estimates of β (se) of 0.28 (0.07) and 2.25 (0.14), which are sig-
nificantly different (P < 0.001). As a consequence, one might consider to report both results separately and not as a single pooled estimate.
Specific features
Heterogeneity and inconsistencyIn the literature, inconsistency, that is, the difference between the results of the direct and indirect compari-sons, has been emphasised by many authors as a special phenomenon that could jeopardise the pooling of all the results3,4,12,13. Furthermore, it has been argued that the results of indirect comparisons are less valid than those based on direct com-parisons14 and when comparing the 
results of indirect with the results of direct comparisons the latter should be the gold standard15. Of course, studies being part of an indirect comparison might well differ in characteristics of design or popula-tion. This could occur when the trials at issue used different inclusion crite-ria. Song et al.16 describes an example in which trials of intervention A ver-sus B were all carried out in primary care and trials of intervention A ver-sus C in secondary care. This means that the indication for which the contrast was investigated was differ-ent between the trials and, of course, studies included in a meta-analysis 
should have comparable study popu-lations (i.e. comparable study ques-tions). Another reason could be that imperceptibly different study popula-tions are included. In the same study, Song et al.16 describes an example where in one study  antibiotics A and C are investigated in patients whose pathogenic bacteria are sensitive to both antibiotics and that in a second study antibiotics B and C are investi-gated in patients with the same indi-cation, whose pathogenic bacteria are resistant to antibiotic B. In both cases the reasoning is that an indirect comparison of A versus B, based on the two trials would be invalid. These 
explanations for effect modifica-tion, perceptible or imperceptible, will affect the validity of the results, but there is no reason to believe that this only happens when indi-rect comparisons are investigated. 
As effect  modification can affect both direct and indirect comparison, we think that inconsistency should be described as a part of the heterogene-ity as we demonstrated in Figures 1 and 2. At any rate, with our approach it is possible to compare the results of the direct and indirect comparisons and test this ‘inconsistency’ param-eter. This is shown in Table 2.The results of the direct and indi-
rect comparisons do not significantly differ. In fact, Figure 1 shows that 
the significant heterogeneity in the 
coefficients describing the difference between ‘individual counselling’ and ‘no contact’ originates from the direct comparisons. It is important to note that the assessment of het-erogeneity, including inconsistency, 
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should not only rely on statistical 
significance testing alone. In fact, we are interested whether the direct and indirect estimates are similar enough to be pooled. A possible approach would be, similar to the analysis of non-inferiority or equivalence stud-ies, to specify a priori what differ-ence between the point estimates of direct comparisons or between direct and indirect estimates (or, 
more strictly, their 95% confidence interval boundaries) is considered to be a clinically meaningful difference. If the difference between the esti-mates of direct comparisons or the difference between direct and indi-rect comparison is larger than such a 
predefined threshold value, the con-sequence would be not to pool the evidence and, where relevant, report the results for different strata. This problem of unexplained heteroge-neity within the direct comparisons is demonstrated in Figure 2. There is clearly a difference in treatment effect between two groups of studies 
and this difference may well be suffi-
ciently large to influence the decision about which treatment to use. How-ever, there is no clear explanation for this difference. Taking the weighted mean and increasing the variance is not the optimal solution to handle this inconsistency.
Random intercept modelAn alternative way of modelling the data would be to assume a nor-mal distribution for the intercepts. Although a random intercept model can easily be implemented, there are 
two reasons to use a fixed intercept model. First, this model generates 
estimates of the study intercepts αi. This makes it possible to check their distribution and, for example, detect outliers (i.e. studies with extremely low or high chances to stop smoking in the reference group), here the ‘no contact’ condition (see Figure 3). 
Second, a fixed-effect model depends on fewer assumptions, that 
is, no normality assumption for the distribution of intercepts and there-fore may be more reliable, depending on the degree to which the assumption is violated. A reason to use a random intercept model would be that this reduces the number of parameters and 
increases statistical efficiency. In our example the number of parameters is 
five in a random intercepts model and 
27 in a fixed- intercepts model. The fit of this model with a binary outcome is dependent on the minimum number of cases and non-cases17. As the number 
of cases is 2072 and non-cases 14 665, we can easily afford to estimate 22 additional parameters. In general the number of observations will be much larger than the number of param-
eters in a fixed-intercepts model. This implies that there is no urgent reason to use a random intercepts model for 
efficiency reasons. 
Expanding the model to studies with 
interval-scaled outcomes Our approach can also be used when for each treatment arm means and standard deviations of interval-scaled outcomes are reported. Con-ventional pooling is based on the assumption that the outcome vari-able is normally distributed. Using the same assumption of a normal distribution of the outcomes, a data set can be generated which is compa-rable to the original data set of indi-vidual  values, except for individual level information on covariates. Assume that in a treatment arm N persons are included with a spe-
cific mean and standard deviation. Drawing N values from a normal distribution with these parameters will result in a sample with a mean and standard deviation. By chance, these parameters will be somewhat 
Figure 3: Histogram of the intercepts of the 24 studies. The intercept of a specific study represents the LnOdds of stopping to smoke in persons who received the reference treatment, in our case ‘no contact’. This can be interpreted as a measure of the propensity to stop smoking when no treatment is given and may serve as a proxy for the severity of smoking addiction in the trial population at issue.
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 different from the original param-eters, but a simple linear transforma-tion can adjust for these differences. For all the treatment arms such a data set can be generated that leads to the same likelihood function as that from the original data and that can be used as input for a suitable linear regression model. Analogous with the foregoing, all sources of var-iation can be investigated and mod-elled. We have applied this method in several studies14,18–20.
DiscussionThe approach proposed here is based on ordinary regression models and therefore is a transparent, easy to implement and valid method that gives estimates of effect parameters with its variances using all available information (i.e. results of direct and indirect comparisons). This method is equivalent to performing an analy-sis with pooled data from all partici-pating studies. It can only be applied if all studies have been randomised with balanced potentially confound-ing factors across treatment arms. However, this limitation holds for all meta-analyses that do not use indi-vidual patient data.Applying this method to 24 stud-ies investigating the effect of four different interventions for smoking cessation, we demonstrated that the method works well and by investigat-ing the mechanisms of heterogeneity we exposed some incongruities that needed further exploration. Exami-nation of such incongruities should be a part of each analysis, but we 
could not extract sufficient informa-tion from the studies.  Furthermore, the primary goal was to demon-strate the performance of our net-work analysis and to show the need of a thorough examination of  heterogeneity.At present, the most frequently used approach to do network analy-sis including studies with three or more arms is the Mixed Treatment 
 Comparisons based on a  Bayesian model2. This method assumes a number of prior distributions and together with the likelihood based on the data collected in the studies, the posterior distribution of the effect parameters is determined. However, the estimates used for indirect com-parisons are not independent and respective correlations are generally unknown. In Table 1, the results of two different Bayesian models are shown. The result of the Bayesian 
fixed-effect model was quite simi-lar to the results of Hasselblad5 and our results.  However, the results of the Bayesian random effects model showed substantial differences when self-help and group counsel-ling with no contact were compared. This could be caused by the fact that the data on the direct comparison in these two cases are sparse (4 and 3 studies, respectively). It is known that the result of a  Bayesian model may be highly dependent on the prior distribution when data is sparse, pos-sibly leading to these considerable deviations21. Furthermore, the use of a different likelihood function with additional parameters and assuming 
a normal distribution of the coeffi-cients could also be an explanation. Our method has a number of attractive features. First, it is a straightforward generalisation of the 
fixed-effects meta-analysis and we have applied the method in several network analyses22–25. Second, it is based on well-known procedures of logistic regression. Third, all assump-tions made may be checked against the data. Fourth, the analysis is based on data on the (notional) patient level, meaning that studies with three or more treatment arms can be included as every patient is entered in the analysis only once. Fifth, the regres-sion model preserves randomisation. Moreover, with the intercept param-eters, the similarity of the studies and possible causes for heterogeneity can be investigated. Sixth, estimates of 
direct and indirect comparisons are easily available. Seventh, the method avoids overweighting small studies as all random effects models do, which may not be desirable7. This method ensures that each patient, irrespec-tive of the size of the study s/he par-ticipated in, contributes in the same 
way to estimating the coefficients. Eighth, no additional assumptions are needed for the zero cell problem (like adding 0.5). The regression model will produce an estimate, correctly taking into account the information from the zero cell arms, provided 
not all arms of a specific treatment contain zero cell counts. Ninth, this model and the resulting estimates allow checking the assumptions needed to model the effect param-eters, in particular whether the effect parameters can be assumed to follow a normal distribution. Tenth, if neces-sary and warranted, a random effect model may be used. Finally, causes of heterogeneity (and inconsistency) can be investigated by examining the 
influence of population and design characteristics on the effect param-eters (meta-regression in network analysis).
ConclusionThese advantages lead us to pro-
pose this method either as the first method of analysis, or to compare to the Bayesian approach. Because of the directness and transparency of the method we also advocate its use in meta-analyses of direct com-parisons only.
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